CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

詳細情報 詳細情報について

• CRID

  1050581246231053824

• NII論文ID

  120005774022

• DOI

  10.1007/s00262-015-1675-7

• ISSN

  14320851

  03407004

• PubMed

  25754123

• Web Site

  https://asahikawa-med.repo.nii.ac.jp/records/5500

  http://link.springer.com/content/pdf/10.1007/s00262-015-1675-7.pdf

  http://link.springer.com/article/10.1007/s00262-015-1675-7/fulltext.html

  http://link.springer.com/content/pdf/10.1007/s00262-015-1675-7

• 本文言語コード

  en

• 資料種別

  journal article

• データソース種別

  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN
  • OpenAIRE